Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies Partners With Blockchain Group Project Shivom

NEW YORK (GenomeWeb) – Australian molecular diagnostics firm Genetic Technologies announced today that it has partnered with Omix Ventures to develop and access a global genomic data management platform for cancer diagnostic development.

Omix Ventures is the parent organization of Project Shivom, which is developing a decentralized genomic data ecosystem called Global Genome ID based on blockchain — a technology for securely tracking and recording online transactions in a way that cannot be manipulated by any one entity.  

Under the terms of the deal, Genetic Technologies will provide Project Shivom with sample processing and other services through its CLIA lab in Victoria. Additionally, the company will be able to use Global Genome ID data to develop new predictive cancer tests, as well as data-monitoring and risk-assessment kits and services. Genetic Technologies also anticipates becoming a member of Project Shivom's laboratory and genetic counseling networks.

Additional terms of the nonbinding agreement were not disclosed.

"Access to such a large database of genomic data would allow [Genetic Technologies] to utilize its SNP-based risk assessment technologies and Australian CLIA accredited laboratory to facilitate the potential further development of other predictive cancer tests," Genetic Technologies Chairman Paul Kasian said in a statement.

Genetic Technologies offers the BrevaGenplus breast cancer risk assessment test and is developing additional cancer risk assessment products including one for colorectal cancer. Last month, the company said it was exploring business opportunities with blockchain technology firm Blockchain Global.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more